Dry Eye

A look back at some of the biggest stories in ophthalmology in 2023.

Dr Amy Nau outlines her comprehensive strategy for addressing Demodex infestations and explains how she combines therapies to manage multifactorial dry eye disease.

Amy Nau, OD, discusses a challenging case of Demodex infestation in a 32-year-old male suffering from severe anxiety due to Rosacea and Demodex.

Amy Nau, DO, presents another case of Demodex in a female patient, highlighting the multifaceted approach required for successful treatment.

Dr Amy Nau shares a patient case involving a female with Demodex infestation, ultimately treated with lotilaner.

Kelly K. Nichols, OD, MPH, PhD, FAAO, and A. Paul Chous, OD, FAAO, recap the diverse topics at EyeCon 2023, emphasizing the collaborative spirit between optometrists and ophthalmologists in addressing issues such as myopia management, diabetic eye conditions, cataract surgery, and patient referrals.

According to the company, an additional trial is required to show positive effects on the treatment of ocular symptoms in dry eye disease.

2 cases illustrate the importance of ocular surface optimization.

Using the NEI protocol for addressing corneal staining, researchers used 5 microliters of 2%, non preserved fluorescein and then evaluated corneal staining.

By taking a proactive approach to treatment, identify the “silent sufferers.”

According to Sun Pharmaceutical Industries, the study design mirrors real-world experience with dry eye disease, including allowing use of artificial tears and measurement of CFS in all 5 corneal zones.

The FDA recalled 26 eye drops due to risk of infection and possible vision loss.

These toxic offenders can be found in various pathways and can pollute the ocular surface.

Educating patients about the importance of consistent care is key.

TearCare provides significant improvements in dry eye signs and symptoms, superior to Restasis in tear film break-up time improvements.

Dr David Kading explores various treatment options for MGD, including thermal pulsation and light-based therapies such as low-level and intense pulsed light (IPL).

Dr David Kading elaborates on the diagnostic criteria for MGD and provides insights into his interpretation of meibography and meibomian gland expression results.

Dr David Kading shares a patient case of MGD demonstrating gradual improvement through thermal pulsation therapy.

Dr David Kading presents a case of MGD associated with extreme inflammatory reaction.

Retain patients and recapture dropouts with a tandem approach.

Collaboration between ophthalmologists, optometrists can boost early detection.

A rapid fire session details what's in the pipeline for ocular surface dryness therapies.

Aldeyra Therapeutics encounters a significant setback, with its stock value plummeting nearly 70%. The FDA indicates a potential Complete Response Letter (CRL) for reproxalap, a dry eye treatment, despite a scheduled Prescription Drug User Fee Act (PDUFA) date of November 23, 2023.

Tracy Doll, OD, FAAO, chats about the AAOpt session "Sunny With a Chance of Tears: What's in the Forecast for Ocular Surface Dryness Therapies?"

Lisa Hornick, OD, MBA, FAAO, chats about her AAOpt presentations, "Dry Eye Jeopardy" and "Sunny with a Chance of Tears of Tears: What's in the Forecast for Ocular Surface Dryness Therapies."

Hear what is new in the world of ocular surface disease, and what's coming down the pipeline.

At AAOpt, Justin Schweitzer, OD, FAAO, and Selina McGee, OD, FAAO, Dipl ABO, discuss the intersection of dry eye and glaucoma.

Bausch + Lomb is gearing up for the American Academy of Optometry (AAOpt) annual meeting, which is poised to convene in New Orleans from Oct. 11-14, 2023.